ArticleVeterinary sciences2025
Water-Soluble Vitamins (Riboflavin, Niacin, Pantothenic Acid) in Dogs with Chronic Liver Disease vs. Healthy Controls.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWater-soluble vitamin deficiencies are common in human chronic liver disease (CLD) due to impaired metabolic pathways. Vitamins B2 (riboflavin), B3 (niacin), and B5 (pantothenic acid) assume critical roles in hepatic and lipid metabolism and may exert hepatoprotective effects. In canine CLD, data beyond cobalamin are sparse, and no guidelines currently endorse B-vitamin supplementation.
methodsThis case-control study analysed 66 stored serum samples from client-owned dogs with CLD and 50 from healthy blood-donor dogs. CLD diagnosis required persistent (>2 months) elevation of at least two liver enzymes (ALP, GGT, AST, ALT) and ultrasonographic evidence of CLD. Serum vitamin concentrations were quantified by LC-MS/MS (ng/mL).
resultsVitamin B2 was significantly lower in CLD dogs versus controls (median 48.4 vs. 85.5 ng/mL;
conclusionsReduced B2 may reflect impaired hepatic processing or absorption in canine CLD. The presence of normal or elevated B3 and B5 may relate to alternative metabolic pathways. This constitutes the first study assessing B2, B3, and B5 in canine CLD, underscoring riboflavin's potential interest in CLD dogs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.